Ceruloplasmin is a copper-containing ferroxidase that is essential for normal iron homeostasis. Whereas ceruloplasmin in plasma is produced and secreted by hepatocytes, in the brain a glycosylphosphatidylinositol (GPI)-anchored form of ceruloplasmin is expressed on the surface of astrocytes. By using a cDNA cloning approach, we have now determined that the GPI-anchored form of ceruloplasmin is generated by alternative RNA splicing. The splicing occurs downstream of exon 18 and replaces the C-terminal 5 amino acids of the secreted form with an alternative 30 amino acids that signal GPI anchor addition. RNase protection analysis demonstrates that the GPI-anchored form is the major form in the brain, whereas the secreted form predominates in the liver. Individuals with aceruloplasminemia, a hereditary deficiency of ceruloplasmin, have severe iron deposition in a number of organs, including the brain where it results in neurodegeneration. Therefore, this novel GPI-anchored form of ceruloplasmin is likely to play an important role in iron metabolism in the central nervous system.
Iron plays an important role in many biological processes. It is an essential cofactor for a variety of enzymes, including ribonucleotide reductase and aconitase, and its presence in heme imparts the ability of hemoglobin to transport oxygen and the ability of cytochrome oxidase to reduce oxygen to water. However, free iron is highly toxic because of its ability to generate free radicals. Ferrous (Fe(II)) iron can generate the highly reactive superoxide and hydroxyl radicals in the presence of molecular oxygen (1) . Consequently, iron metabolism is tightly regulated, and a variety of proteins have evolved to bind, transport, and sequester iron (2) . Transferrin, the major iron transport protein in plasma, transports iron from sites of storage, such as the liver, to tissues utilizing iron. Ceruloplasmin, the major ferroxidase in plasma (300 -400 g/ml), promotes iron incorporation into transferrin as transferrin only binds ferric (Fe(III)) iron (3) .
Direct evidence for a role of ceruloplasmin in iron metabolism in vivo is provided by studies of patients with aceruloplasminemia, a hereditary deficiency of ceruloplasmin due to null mutations in the ceruloplasmin gene (4 -6) . These patients have severe iron deposition in a variety of organs, including the brain where it results in neurodegeneration. The neurodegeneration appears to be due to an increased generation of free radicals by the accumulated iron. Indeed, there is a dramatic increase in the levels of lipid peroxidation products in the cerebrospinal fluid of patients with aceruloplasminemia (7) . A number of other neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and Hallervorden-Spatz disease are also associated with abnormal iron deposition and free radical injury in the central nervous system (CNS) 1 (8) . Although ceruloplasmin is generally considered a plasma protein secreted by the liver, we recently demonstrated that a membrane-bound glycosylphosphatidylinositol (GPI)-anchored form of ceruloplasmin is localized to the surface of astrocytes in the CNS (9) . Hepatocytes, which produce the ceruloplasmin present in serum, do not express the GPI-anchored form. The transcript coding for serum ceruloplasmin has been cloned from human (10) , rat (11) , and mouse (12) liver cDNA libraries, and only a single gene has been identified (13) . This report describes the cloning and expression of a novel alternatively spliced transcript for the GPI-anchored form of ceruloplasmin. We also demonstrate that, in contrast to the liver which expresses mainly the secreted form, the brain expresses primarily the GPI-anchored form of ceruloplasmin. Since a lack of ceruloplasmin leads to excessive iron deposition in the brain and neurodegeneration, the GPI-anchored form of ceruloplasmin likely plays a crucial role in iron metabolism in the CNS.
EXPERIMENTAL PROCEDURES
Screening of the cDNA Library-In order to screen the cDNA library, a probe proximal to the 3Ј end of the open reading frame (ORF) of the rat serum ceruloplasmin transcript was generated by RT-PCR using primers based on published sequence (Ref. 11; GenBank TM accession number, L33869). The primers were FP1 (forward primer), 5Ј-GCA TGC TCG GTC CAC TGA TTC-3Ј, and RP1 (reverse primer), 5Ј-AAC ATT TTC CCA TTG ATA GCA T-3Ј. These primers amplify a 481-base pair product corresponding to nucleotides 2399 -2879 of the ORF of the rat serum ceruloplasmin transcript.
The probe was used to screen an oligo(dT)-primed rat C6 glioma cDNA library prepared by D. Feinstein (Cornell University). The library was made in Lambda Zap II using the EcoRI-XhoI directional cloning procedure and contained an original complexity of 1 ϫ 10 6 clones. 3 ϫ 10 5 clones were screened according to Sambrook et al. (14) . Twenty positive clones were obtained and were purified by two subsequent rounds of screening with the same probe. Two of the largest cDNA inserts were sequenced by automated fluorescence sequencing * This work was supported by a grant from the Canadian Medical Research Council (to S. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The (Bio S&T). The complete sequences were aligned with the published sequence for rat serum ceruloplasmin (11) using the program MegAlign (DNASTAR).
Transfections-Full-length cDNA clones were generated by RT-PCR using the Perkin-Elmer XL PCR kit according to the manufacturer's instructions. The cDNA for the GPI-anchored form of ceruloplasmin was amplified from C6 glioma RNA using the following primers: CFP1 (common forward primer), 5Ј-GAC CTC GAG ATC GCG GGC TCC AAG AGG-3Ј, and GPIRP1 (GPI reverse primer), 5Ј-GAC GGA TCC ATT TAA ATA TGG CGT GAT AGC ACA-3Ј. The cDNA for the secreted (serum) form of ceruloplasmin was amplified from rat liver RNA using the following primers: CFP1 and SRP1 (serum reverse primer), 5Ј-GAC GGA TCC TTC ATC TGT CCA TCG GCA TTA CC-3Ј. To generate the expression construct, the PCR products were subcloned into the mammalian expression vector pEUK-C1 (CLONTECH).
For the transfections, human embryonic kidney 293T (HEK 293T) cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, vitamins, and penicillin/streptomycin (Life Technologies, Inc.) on either 60-mm culture dishes or 12-mm poly-L-lysinecoated glass coverslips in 24-well cell culture plates until 50 -70% confluent. Calcium phosphate-mediated transfections were performed using the ProFection system (Promega). The medium was replaced 24 h following the transfection and immunocytochemistry was performed the following day on live cells grown on the coverslips. At the same time, the cells and conditioned media were harvested from the 60-mm dish cultures for immunoprecipitations and immunoblotting.
Immunocytochemistry and PI-PLC Treatment-Immunocytochemistry was performed on live cells grown on coverslips using a monoclonal antibody to ceruloplasmin (mAb 1A1; see Ref. 9 ) and visualized with a goat anti-mouse IgG antibody conjugated to fluorescein (Jackson ImmunoResearch) as described previously (9) . For some experiments, cells transfected with the cDNA for GPI-anchored ceruloplasmin were treated with phosphatidylinositol-specific phospholipase C (PI-PLC) before immunocytochemistry. Cells transfected in 60-mm dishes were harvested with Hanks' balanced salt solution (Life Technologies, Inc.) containing 5 mM EDTA (pH 7.4) and resuspended in 200 mM (isotonic) triethanolamine (pH 7.4). 1 ϫ 10 6 cells were resuspended in a final volume of 250 l containing 5 units/ml protease-free PI-PLC (Roche Molecular Biochemicals) and incubated at 37°C for 60 min. Control cells were treated identically but without PI-PLC. Cells were subsequently washed by centrifugation, plated onto poly-L-lysine-coated glass coverslips for 10 min and immunostained with the mAb 1A1.
Immunoprecipitations and Immunoblotting-Transfected cells were harvested as described above, resuspended in Tris-buffered saline containing 1% Nonidet P-40, 0.05% sodium azide, and protease inhibitors (phenylmethylsulfonyl fluoride, 100 g/ml; aprotinin, 2 g/ml; pepstatin, 1 g/ml), vortexed to extract membrane proteins, and centrifuged. 1-ml aliquots of the resulting supernatants as well as the conditioned media were incubated with purified mAb 1A1 (20 g) for 4 h at 4°C, and then 100 l of packed protein A beads (Amersham Pharmacia Biotech) were added and incubated for another 4 h at 4°C. Beads were washed with Tris-buffered saline containing 1% Nonidet P-40, extracted with SDS-polyacrylamide gel electrophoresis sample buffer, and the supernatants were electrophoresed and blotted onto polyvinylidene difluoride membrane. Western blotting was performed as described previously (9), using a polyclonal rabbit anti-ceruloplasmin antibody (Dako).
Ribonuclease (RNase) Protection Assay-The ceruloplasmin probe for the RNase protection experiments was generated by RT-PCR using rat brain RNA. The primers used were GPIFP1 (GPI forward primer), 5Ј-GTA TGT GAT GGC TAT GGG CAA TGA-3Ј, and GPIRP2 (GPI reverse primer), 5Ј-CCT GGA TGG AAC TGG TGA TGG A-3Ј. These primers amplify a product of 449 base pairs from the transcript for the GPI-anchored form of ceruloplasmin, corresponding to nucleotides 2928 -3376 of the ORF. The product was subcloned into pGEM-T (Promega) and sequenced using the ThermoSequenase kit (Amersham Pharmacia Biotech) and the OpenGene automated sequencer (Visible Genetics).
The RNase protection assay was performed as described previously (15) . The pGEM-T plasmid containing the ceruloplasmin insert was linearized with either NotI or NcoI and transcribed using either T7 RNA polymerase (antisense probe) or Sp6 RNA polymerase (sense probe), respectively, using [ϰ-
32 P]CTP to label the probe. The probe was gel-purified and 1 ϫ 10 6 cpm hybridized with 20 g of total RNA from either rat liver, C6 glioma cells, neonatal (postnatal day 3) rat brain, or adult (2-month-old) rat brain in 80% formamide solution at 65°C overnight. The samples (500 l) were then treated with 2 l of RNase mixture (5 units/l RNase A and 0.25 units/l RNase T1) for 30 min, followed by 20 l of proteinase K (10 mg/ml) at 37°C. Samples were precipitated and analyzed by electrophoresis on a 5% polyacrylamide, 8 M urea gel. This probe yields a 449-nucleotide protected fragment for the GPI-anchored form of ceruloplasmin and a 236-nucleotide fragment for the secreted form. The rat glyceraldehyde-3-phosphate dehydrogenase probe (Ambion) generates a 316-nt protected fragment. The sizes of the protected fragments were confirmed using an RNA ladder generated by transcribing fragments of known size.
RESULTS
Cloning of a Novel cDNA for Ceruloplasmin-Our previous biochemical data indicated that the GPI-anchored form and the secreted (serum) form of ceruloplasmin were highly similar, suggesting that they probably differed only in the extreme C terminus (9) . In order to clone the putative alternatively spliced transcript for the GPI-anchored form of ceruloplasmin, an oligo(dT)-primed C6 glioma cDNA library was screened with a probe proximal to the end of the ORF for the secreted form of rat ceruloplasmin (11) . Twenty clones were obtained with insert sizes that ranged from 1 to 3.6 kb. Complete DNA sequences for two of the larger clones (insert sizes of 2.9 and 3.6 kb) were aligned with the cDNA sequence for the secreted form of rat ceruloplasmin (11) . This analysis revealed that both clones encoded a novel transcript that was essentially identical to that for secreted ceruloplasmin except for a short terminal segment of the ORF as well as the 3Ј-untranslated region. The largest (3.6 kb) cDNA clone contained the complete ORF for this alternatively spliced form of ceruloplasmin as well as 12 nucleotides of 5Ј-untranslated region and 260 nucleotides of 3Ј-untranslated region. A comparison with the known exonintron boundaries of human serum ceruloplasmin (16) reveals that the novel cDNA differs from the cDNA for the secreted form downstream of exon 18 (nucleotide 3163 of the ORF). This alternatively spliced transcript encodes a protein of 1084 amino acids compared with 1059 amino acids for secreted ceruloplasmin. The mature proteins, lacking the leader peptide of 19 amino acids, are 1065 and 1040 amino acids, respectively (Fig.  1) . The ORF of the novel cDNA substitutes the C-terminal 5 amino acids of secreted ceruloplasmin with 30 alternative amino acids.
The alternative stretch of 30 amino acids is predominantly non-polar, as it is for all known GPI-anchored proteins, with a large fraction of hydrophobic residues (Fig. 1) . In addition, this stretch of amino acids also contains, proximally, a potential site for GPI anchor addition. GPI anchors are added to a small The final eight common amino acids are boxed. The five C-terminal amino acids of the secreted form are replaced by 30 amino acids in the alternatively spliced form that serve as a GPI anchor addition signal. The stretch of hydrophobic amino acids that signal GPI anchor addition are underlined. The best candidate amino acid for GPI-anchor addition is the alanine.
amino acid (denoted the amino acid) upstream of the nonpolar C-terminal signal peptide, with concomitant cleavage of the signal peptide (17) . The first amino acid of the alternative peptide, the alanine, is a good candidate for the position. GPI anchor addition also requires small amino acids immediately following the amino acid, which are denoted the ϩ 1 and ϩ 2 amino acids. The serines immediately following the alanine are ideal candidates for these positions. Thus, it appears that this alternatively spliced ceruloplasmin with its alternative C-terminal tail satisfies all the known requirements for GPI anchor addition.
Novel cDNA Clone Codes for the GPI-anchored Form of Ceruloplasmin-To demonstrate conclusively that the alternatively spliced transcript codes for the GPI-anchored form of ceruloplasmin, full-length cDNA clones for the alternatively spliced form, as well as the secreted form were generated by RT-PCR and subcloned into the pEUK-C1 mammalian expression vector. These ceruloplasmin expression vectors were transfected into HEK 293T cells and analyzed for expression by immunocytochemistry and Western blotting. Cells transfected with the novel cDNA clone demonstrated intense cell surface immunofluorescence labeling with a monoclonal antibody (mAb 1A1) to rat ceruloplasmin (Fig. 2, A and B) . This monoclonal antibody is species-specific and only recognizes native rat ceruloplasmin (9, 18) . In contrast, cells transfected with the cDNA for secreted ceruloplasmin did not show cell surface labeling with the monoclonal antibody to ceruloplasmin (Fig. 2, C and  D) . This lack of staining is identical to that of non-transfected (control) cells (Fig. 2, E and F) . The novel cDNA clone therefore codes for a membrane-bound form of ceruloplasmin.
To confirm that both groups of transfected cells were expressing ceruloplasmin, the conditioned media and detergent extracts of the cells were immunoprecipitated with mAb 1A1 (in order to exclude bovine ceruloplasmin present in fetal bovine serum) and Western-blotted with a polyclonal antibody to ceruloplasmin. The Western blot demonstrates that ceruloplasmin is associated predominantly with the cells when transfected with the cDNA for the alternatively spliced form of ceruloplasmin (Fig. 3) . The estimated size of this protein of 135 kDa is similar to the size of GPI-anchored ceruloplasmin purified from rat astrocytes or C6 glioma cells (9) . In contrast, ceruloplasmin is found predominantly in the culture medium of cells transfected with the cDNA for the secreted form (Fig. 3) . This ceruloplasmin appears slightly smaller (132 kDa) than that produced by the cells transfected with the novel cDNA transcript. The larger size of the latter is consistent with it being GPI-anchored, as the GPI anchor, which is added following cleavage of the C-terminal signal peptide, contributes approximately 1.5-3 kDa to the size of most GPI-anchored proteins, depending on the carbohydrate and lipid composition of the anchor (17) .
Finally, we sought to demonstrate conclusively that the ceruloplasmin expressed on the surface of the cells transfected with the novel cDNA was in fact GPI-anchored and not attached by another means (i.e. a protein anchor). To this end, the transfected cells were treated with PI-PLC, an enzyme that specifically cleaves GPI anchors from GPI-anchored proteins (19) . This treatment eliminated cell surface labeling with the monoclonal antibody to ceruloplasmin (Fig. 4, A and B) . Control cells, transfected with the same clone and treated identically but without PI-PLC, showed strong surface labeling (Fig. 4, C  and D) . These findings provide further evidence that the novel alternatively spliced transcript codes for the GPI-anchored form of ceruloplasmin. 
Expression of the Transcripts for the GPI-anchored and Secreted Forms of Ceruloplasmin-
To estimate the relative abundance of the transcripts for GPI-anchored ceruloplasmin and secreted ceruloplasmin, RNase protection assays were performed on rat brain, liver, and C6 glioma cells, using a probe that spans nucleotides 2928 -3376 of the cDNA for GPI-anchored ceruloplasmin. The probe is fully protected by the transcript for GPI-anchored ceruloplasmin to yield a fragment of 449 nucleotides, and it is partially protected by the transcript for secreted ceruloplasmin to yield a fragment of 236 nucleotides. Adult and neonatal rat brain express almost exclusively the transcript for GPI-anchored ceruloplasmin (Fig. 5) . Only a small amount of the transcript for the secreted form is expressed in the brain. There is no significant difference in expression between adult and neonatal brain. In contrast, rat liver expresses predominantly the transcript for secreted ceruloplasmin although a lower level of the transcript for the GPI-anchored form is also found. C6 glioma cells express predominantly the transcript for GPI-anchored ceruloplasmin, with lower levels of the secreted form. These results indicate that whereas the liver produces predominantly the secreted form of ceruloplasmin, the brain produces, almost exclusively, the GPI-anchored form.
DISCUSSION
The GPI-anchored form of ceruloplasmin was recently identified in our laboratory using protein biochemical techniques (9) . By using a monoclonal antibody (mAb 1A1), ceruloplasmin was shown to be expressed on the surface of astrocytes in the mammalian brain (9) as well as by leptomeningeal cells and fibroblasts in a number of tissues including the liver (18). However, hepatocytes, which produce the ceruloplasmin present in serum, do not express the GPI-anchored form. 2 Our earlier peptide mapping studies indicated that GPI-anchored ceruloplasmin and serum ceruloplasmin are highly similar, suggesting that they probably differ only in the extreme Cterminal segment (9) . The possibility that these two different forms of ceruloplasmin might be produced by alternative RNA splicing was suggested by the work of Mollgard and co-workers (20) . These investigators demonstrated that ceruloplasmin expressed by Xenopus oocytes following microinjection of mRNA from fetal human liver was secreted by the oocytes, whereas injection of mRNA from fetal human brain led to the expression of ceruloplasmin that was retained by the cells. We now show that the GPI-anchored form of ceruloplasmin is generated by alternative RNA splicing and that it is the predominant form in the brain. The complete cDNA sequences for human (10) , rat (11) , and mouse (12) serum ceruloplasmin have been reported previously, and whereas the exon-intron boundaries have been mapped only for the human cDNA (16), the boundaries are likely to be similar in the rat and mouse due to the high degree of sequence conservation (12) . The novel transcript for ceruloplasmin differs from the transcript for secreted ceruloplasmin downstream of exon 18. This alternative splicing leads to the replacement of the final 5 amino acids found in secreted ceruloplasmin with an alternative 30 amino acids in the novel form. This alternative C-terminal tail is relatively hydrophobic and represents a good signal peptide for GPI anchor addition (17) . Transfection of the full-length cDNA for the novel alternatively RNase protections were performed on 20 g of total RNA from C6 glioma cells, rat liver, and adult and neonatal rat brain, using a probe that recognizes both transcripts. The probe is fully protected by the transcript for the GPI-anchored form of ceruloplasmin to yield a 449-nt fragment (GPI Cp), and it is partially protected by the transcript for the secreted form to give a 236-nt fragment (Secreted Cp). An 18-h exposure is shown for the C6 glioma cells and the liver. A 180-h exposure is shown for the brain samples and the tRNA control. C6 glioma cells contain a large amount of the transcript for the GPI-anchored form and a relatively small amount of the transcript for the secreted form. In contrast, liver expresses predominantly the transcript for the secreted form but also expresses a lower level of the transcript for the GPI-anchored form (not visible in the 18-h exposure). Both neonatal and adult brain express primarily the transcript for the GPI-anchored form. tRNA control shows no signal. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control demonstrates that similar amounts of RNA (of comparable quality) were used for the hybridizations.
spliced form of ceruloplasmin into HEK 293T cells confirmed that it does indeed code for a membrane-anchored form of ceruloplasmin. In addition, treating these cells with PI-PLC, an enzyme that specifically cleaves GPI anchors from GPI-anchored proteins, eliminates the cell surface localization of ceruloplasmin. Cells transfected with the cDNA for the secreted form do not express ceruloplasmin on the cell surface but, in contrast, secrete it into the medium. Together, these data indicate that the novel alternatively spliced transcript does, in fact, code for the GPI-anchored form of ceruloplasmin. This membrane-anchored form of ceruloplasmin is expected to retain ferroxidase activity as it maintains all the ligands for the active site copper atoms, and the alternative C-terminal tail is unlikely to affect the overall structure of ceruloplasmin as the C terminus of the secreted protein is located outside the ␤-barrel structure (21, 22) . In keeping with this, we have previously shown that GPI-anchored ceruloplasmin, released from the surface of C6 glioma cells with PI-PLC, possesses oxidase activity (9) .
RNase protection assays on rat brain and liver, using a probe that recognizes transcripts for both the GPI-anchored and secreted forms of ceruloplasmin, showed that the brain expresses almost exclusively the transcript for the GPI-anchored form. In contrast, liver expresses a large amount of the transcript for the secreted form. This is consistent with observations that the liver produces large amounts of ceruloplasmin for secretion into the circulation. In addition, the liver also contains a lower amount of the transcript for the GPI-anchored form that is likely to be expressed by connective tissue fibroblasts.
Because ceruloplasmin from the circulation does not appear to cross the blood-brain barrier and levels of soluble ceruloplasmin in the cerebrospinal fluid are extremely low, at less than 1 g/ml compared with 300 -400 g/ml in plasma (23) , it would appear that the GPI-anchored form, produced within the brain, is the major form of ceruloplasmin in that organ. Other investigators have reported ceruloplasmin expression in the mammalian CNS, primarily by Northern blot analysis using probes that recognize both alternatively spliced transcripts (24 -26) . In addition, ceruloplasmin has been localized to astrocytes and neurons by immunohistochemistry (20) . More recently, Gitlin and colleagues (12, 27) have localized ceruloplasmin expression by in situ hybridization to various populations of astrocytes in the CNS, with the greatest expression in astrocytes surrounding the brain microvasculature. These and other investigators (12, 27, 28) have also detected ceruloplasmin expression in retinal astrocytes and Muller glia by in situ hybridization. The data we present in this paper suggests that the ceruloplasmin detected in the CNS by these investigators is predominantly the GPI-anchored form.
Why ceruloplasmin is alternatively spliced to produce the GPI-anchored form in the CNS is not known. However, it is known that compared with proteins anchored to the surface by a protein anchor, GPI-anchored proteins, which are found in selectively lipid-enriched microdomains, have a much greater degree of lateral mobility within the lipid bilayer (17) . In addition, the GPI anchor has been identified as an apical targeting signal for various cell types (29) . This combination of features might help achieve a high localized concentration of ceruloplasmin where required, for example in the perivascular processes of astrocytes, and facilitate the interaction of ceruloplasmin with other proteins involved in iron transport. Another unique feature of GPI-anchored proteins is that they can be transferred from the plasma membrane of one cell to another at sites of cell-cell contact (30) . This mechanism might permit cells that do not express GPI-anchored ceruloplasmin to acquire the protein from adjacent astrocytes expressing it. This might be significant in vivo, since ceruloplasmin has been localized to both astrocytes and neurons by immunohistochemistry (20) although neurons do not appear to express ceruloplasmin mRNA (12, 27) .
The role of ceruloplasmin in vivo is most convincingly demonstrated by studies of individuals with aceruloplasminemia, a hereditary deficiency of ceruloplasmin. These patients exhibit severe dementia and movement disorders, associated with iron deposition and neurodegeneration in a number of brain regions, including the striatum and dentate nucleus (4 -6). The neurodegeneration is likely due to the generation of oxygen free radicals via the iron-catalyzed Haber-Weiss reaction. Indeed, Miyajima et al. (7) have observed a large increase in lipid peroxidation products in the cerebrospinal fluid of patients with aceruloplasminemia. Furthermore, treating patients with the iron chelator desferrioxamine reduces the progression of neurological symptoms (31) .
The iron deposition in the tissues of patients with aceruloplasminemia suggests that the role of ceruloplasmin in vivo is to prevent excessive intracellular iron accumulation. Ceruloplasmin may achieve this by either promoting iron efflux or by inhibiting iron uptake, and recent in vitro data suggest that ceruloplasmin might perform both of these functions. A role for ceruloplasmin in iron efflux was originally suggested by Osaki and colleagues (3), based on the observation that the ferroxidase activity of ceruloplasmin promoted iron incorporation into transferrin. Indeed, in combination with transferrin, ceruloplasmin has been shown to promote iron efflux from cells in vitro (32) . A potential role for ceruloplasmin in iron efflux from cells is also suggested by the recent identification of a ceruloplasmin homologue, named Hephaestin, which is expressed by the intestine and which is required for the movement of iron out of intestinal epithelial cells (33) . Mice mutant for Hephaestin are unable to release iron from the intestinal epithelial cell, where it accumulates, and consequently the animals have severe anemia. Interestingly, Hephaestin, which is 50% homologous to ceruloplasmin and thought to possess ferroxidase activity, is a transmembrane protein that appears to be localized to the surface of intestinal epithelial cells. Hephaestin is thought to interact with an iron transport protein to permit the efflux of iron out of these cells. The GPI-anchored form of ceruloplasmin could potentially perform a similar function, promoting iron efflux from cells in the CNS. This putative interaction of a ferroxidase with an iron transport protein has certain similarities with an iron uptake system in yeast in which a cell surface ferroxidase, Fet3, is required for iron uptake by an iron transport protein, Ftr1 (34, 35) . However, unlike the single-celled yeast, the interaction of the GPI-anchored ceruloplasmin with an iron transporter on mammalian cells may lead to iron release rather than uptake.
In addition to promoting iron efflux, ceruloplasmin might also prevent intracellular iron accumulation by inhibiting iron uptake by a transferrin-independent iron uptake system that has been identified in various cell types (2) . This system requires the reduction of Fe(III) iron to Fe(II) iron at the cell surface for uptake to occur (2) . This iron uptake system might be particularly important for cells that do not express the transferrin receptor, such as astrocytes (36) . As a ferroxidase, ceruloplasmin would counteract this reduction of iron at the cell surface and thus limit uptake by this system. Indeed, this possibility is supported by the observation that ceruloplasmin inhibits iron uptake by a transferrin-independent iron uptake system in vitro (37) .
It is not known if the lack of GPI-anchored ceruloplasmin in the CNS is directly responsible for the iron deposition and neurodegeneration seen in aceruloplasminemia or whether this is a secondary consequence of the systemic iron overload. However, in the most common disorder of iron metabolism, hereditary hemochromatosis, severe iron deposition occurs in most systemic organs, including the liver, but iron deposition does not occur in the CNS, and consequently, neurological symptoms are not observed (38) . This suggests that the lack of GPI-anchored ceruloplasmin in the CNS is likely to be primarily responsible for the iron deposition and neurodegeneration in aceruloplasminemia. Whether a reduction in the level of GPIanchored ceruloplasmin in specific regions of the CNS might contribute to the pathology seen in a variety of neurodegenerative diseases in which excessive iron accumulation occurs needs to be examined.
